Ajanta Pharma Limited has formally confirmed that it does not fall under the definition of a ‘Large Corporate’ entity. In its latest regulatory disclosure, the company stated that it had nil outstanding borrowing as of March 31, 2026. This classification confirms that the company is currently not subject to the mandatory borrowing requirements and frameworks established for large-scale corporate entities.
Financial Position and Borrowing Status
In a recent filing dated April 1, 2026, Ajanta Pharma provided a mandatory initial disclosure regarding its corporate status. The company explicitly declared that it is not categorized as a ‘Large Corporate.’ As part of this assessment, the company reported zero outstanding borrowings as of the fiscal year-end, March 31, 2026.
Credit Rating and Compliance
Alongside its status confirmation, the company provided details regarding its credit profile for the previous fiscal year. Ajanta Pharma holds a high-standing credit rating of CARE A1+, issued by CARE Ratings Limited. While the company is not currently subject to the specific framework for large entities, it identified the National Stock Exchange (NSE) as the designated venue for disclosures should its status change in the future.
Source: BSE
